CA-125 Test in IndiaThe Most Ordered — and Most Misunderstood — Blood Test in Gynaecology: The Complete Patient Guide
CA-125 Interpretation · ROMA Score · HE4 · Endometriosis vs Cancer · Tumour Marker Costs · Myths Busted
⚡ Key Facts at a Glance — CA-125 Test in India
What Is the CA-125 Test?
CA-125 stands for Cancer Antigen 125 — it is a protein (technically a glycoprotein) that sits on the surface of many types of cells in the body. In healthy women, small amounts of CA-125 are produced by cells lining the abdominal cavity (peritoneum), the fallopian tubes, the endometrium (uterine lining), and the lungs and heart linings — and small amounts are released into the bloodstream.
CA-125 levels rise when these cells are inflamed or irritated (as in endometriosis or pelvic infection), reproducing abnormally (as in cancer), or shed in larger amounts than normal (as happens during menstruation or in the first trimester of pregnancy). The CA-125 blood test measures the concentration of this protein in the blood, expressed in units per millilitre (U/mL). The standard 'normal' upper limit is 35 U/mL — though some specialist centres use 21 U/mL as a tighter threshold.
Why CA-125 Cannot Be Taken Out of Clinical Context
The fundamental challenge with CA-125 is that it is not specific to cancer. The same protein that ovarian cancer cells shed is also shed by inflamed endometrial-like cells in endometriosis, by irritated peritoneum during PID, by the developing placenta in early pregnancy, and by a liver that is not clearing the protein efficiently. An elevated CA-125 tells us 'something is causing more of this protein to be released than usual' — but not what. This is why CA-125 must ALWAYS be interpreted in combination with the patient's age, symptoms, ultrasound findings, HE4 (ROMA score), and clinical history.
CA-125 Levels — Interpretation Guide for Patients
The table below shows how different CA-125 levels should be interpreted — and crucially, why the same number can mean completely different things in different clinical contexts. The number alone never tells the full story.
| CA-125 Level | Interpretation | Clinical Significance and Recommended Action |
|---|---|---|
| <21 U/mL | VERY REASSURING | Ideal result. Extremely low probability of ovarian cancer. In post-menopausal women with any ovarian mass, this range is very reassuring. Used as a tighter threshold in some specialist centres. |
| 21–35 U/mL | NORMAL | Below the standard laboratory threshold of 35 U/mL. In a woman with a normal ultrasound and no clinical symptoms, this is reassuring. However, a rising trend from 15 → 28 → 34 over 3 measurements (each 'normal') is more clinically concerning than a stable 40 U/mL in a woman with known endometriosis. |
| 35–65 U/mL | MILDLY ELEVATED — Clinical correlation essential | The most clinically nuanced range. In a pre-menopausal woman with endometriosis, fibroids, or active PID — this is almost certainly benign. In a post-menopausal woman with a new ovarian mass — this requires urgent specialist evaluation. Context is everything. Repeat in 4–8 weeks if uncertain. |
| 65–100 U/mL | MODERATE ELEVATION — Specialist evaluation strongly advised | At this level, even with known benign conditions, specialist evaluation is warranted. Ultrasound + ROMA score calculation essential. If ultrasound shows complex ovarian mass — urgent Gynecologic Oncology referral. |
| >100 U/mL | HIGH — Urgent specialist evaluation | This level significantly raises concern for malignancy — particularly in post-menopausal women. Perform: IOTA-protocol ultrasound, HE4, full blood count, CT abdomen + pelvis. However, even at this level, endometriosis can produce CA-125 >100 U/mL in pre-menopausal women. |
| >200 U/mL | VERY HIGH — Oncological evaluation urgently | High clinical suspicion for malignancy in post-menopausal or peri-menopausal women. Urgent CT + specialist referral. In young women with Stage IV endometriosis, CA-125 can occasionally reach this level — but this is rare and requires specialist discrimination from cancer. |
| Falling levels (post-treatment) | EXCELLENT SIGN — Treatment is working | In a woman being treated for gynaecological cancer, a steadily falling CA-125 confirms that the cancer is responding to treatment. Each measurement should be declining — a plateau or rise requires reassessment of the treatment plan. |
| Rising levels (post-treatment, previously in remission) | CONCERNING — Possible recurrence | A rise in CA-125 from the post-treatment nadir (lowest point), particularly when consistent across 2–3 measurements, is the most sensitive early indicator of cancer recurrence — often preceding imaging or symptoms by 2–6 months. Prompt restaging assessment required. |
Conditions That Cause CA-125 Elevation — Benign and Malignant
One of the most important facts about CA-125 is that the majority of elevated CA-125 results in women of reproductive age are caused by completely benign conditions. Understanding this prevents unnecessary anxiety while still ensuring appropriate investigation.
| Condition | Nature | How and Why It Elevates CA-125 |
|---|---|---|
| Endometriosis | BENIGN — Very Commonly Elevated | One of the most common causes of significantly elevated CA-125 in pre-menopausal women. Stage III–IV endometriosis can produce CA-125 levels of 50–300+ U/mL. CA-125 alone cannot distinguish severe endometriosis from ovarian cancer — ultrasound (IOTA criteria), HE4, and clinical context are essential. |
| Uterine Fibroids (Leiomyomas) | BENIGN — Mildly Elevated (usually <65 U/mL) | Large or multiple fibroids cause mild CA-125 elevation — thought to reflect mechanical irritation of the peritoneal surface. Almost always below 65 U/mL. In a woman known to have fibroids, mild CA-125 elevation rarely warrants further investigation unless ultrasound reveals new concerning features. |
| Pelvic Inflammatory Disease (PID) | BENIGN — Moderately to Significantly Elevated | Active pelvic infection causes significant CA-125 elevation — the acute inflammation mimics the peritoneal irritation seen in advanced ovarian cancer. CA-125 can be >100 U/mL in severe PID. Resolves completely with appropriate antibiotic treatment. |
| Pregnancy (First Trimester) | BENIGN — Normal physiological elevation | CA-125 rises in the first trimester as the developing placenta and decidua shed CA-125 into the maternal circulation. Levels typically peak at weeks 8–12 then decline. Always inform the requesting doctor if there is any possibility of pregnancy. |
| Menstruation | BENIGN — Mild, Transient Elevation | CA-125 can be mildly elevated (up to 50–60 U/mL) during menstruation — particularly on day 1–3 of the period. For the most reliable CA-125 measurement, ideally have the test at least 7–10 days after the period ends. |
| Liver Disease (Cirrhosis, Hepatitis) | BENIGN (in this context) — Moderate Elevation | The liver plays a role in clearing CA-125 from the circulation. In liver disease, elevated CA-125 reflects reduced hepatic clearance rather than gynaecological pathology. LFTs help identify liver disease as the cause. |
| Ascites (from any cause) | BENIGN or MALIGNANT — context determines | Any cause of ascites — whether benign (cardiac failure, liver cirrhosis, TB peritonitis) or malignant (ovarian cancer) — elevates CA-125. Clinical assessment and ascites fluid analysis (diagnostic paracentesis with cytology) distinguish benign from malignant ascites. |
| Ovarian Cancer (Epithelial) | MALIGNANT — Often Significantly Elevated | Elevated in ~80% of advanced (Stage III–IV) ovarian cancers. Only 50–60% of Stage I ovarian cancers show elevated CA-125. Serous cancers more commonly elevate CA-125; mucinous and clear cell carcinomas are less reliably associated. |
| Endometrial Cancer (Advanced) | MALIGNANT — Elevated in Advanced Disease | CA-125 is not a reliable marker for early endometrial cancer. It rises with advanced disease — Stage IIIC (para-aortic lymph node involvement) and Stage IV. Used as a monitoring marker after treatment in advanced endometrial cancer. |
When Is CA-125 Really Mandatory vs. When Should It NOT Be Ordered?
CA-125 is a targeted, clinical-context-dependent test — not a routine annual screening tool. Understanding when it is genuinely necessary — and when it is not — prevents both unnecessary anxiety and false reassurance.
| Clinical Situation | Recommendation | Why CA-125 Is or Is Not Appropriate |
|---|---|---|
| Any woman with a new ovarian mass or complex adnexal cyst on ultrasound | MANDATORY | CA-125 (and ideally HE4 + ROMA score) is a mandatory part of the initial evaluation of any ovarian mass. Combined with ultrasound IOTA criteria, ROMA score provides the most accurate pre-surgical risk stratification — determining whether surgery must be referred to a Gynecologic Oncologist. |
| Post-menopausal woman with any pelvic symptom | MANDATORY | Any post-menopausal woman with persistent BEAT symptoms (Bloating, Eating difficulty, Abdominal pain, Toilet changes) should have transvaginal ultrasound + CA-125 + HE4 as part of the initial evaluation. Post-menopausal ovaries should not produce cysts — any ovarian finding requires urgent evaluation. |
| Before surgery for confirmed or suspected gynaecological cancer | MANDATORY | A pre-operative CA-125 is essential for establishing a baseline to monitor treatment response, informing the surgeon of disease extent, and contributing to staging. |
| During chemotherapy for ovarian or advanced endometrial cancer | MANDATORY | CA-125 before each chemotherapy cycle is the most sensitive, real-time indicator of treatment response. It guides decisions about continuing, changing, or intensifying treatment. |
| Surveillance after treatment for ovarian cancer | MANDATORY — Every 3 months for 2 years, then 6-monthly to 5 years | Serial CA-125 measurement is the cornerstone of post-treatment surveillance. It detects recurrence before imaging or clinical symptoms in the majority of cases. |
| Known endometriosis with new or changed symptoms | STRONGLY RECOMMENDED | In women with known endometriosis who report new or worsening symptoms — particularly post-menopausal women — CA-125 (with HE4) provides additional information alongside repeat ultrasound for assessing whether the disease has changed character. |
| BRCA1/2 carriers or women with Lynch syndrome — annual surveillance | STRONGLY RECOMMENDED | Women with hereditary cancer syndromes who are undergoing annual surveillance typically have CA-125 measured annually alongside transvaginal ultrasound. |
| Routine annual screening in average-risk women (no symptoms, no risk factors) | NOT RECOMMENDED | Routine CA-125 screening in asymptomatic average-risk women is explicitly NOT recommended by ACOG, SGO, FOGSI, and the National Cancer Grid of India. It produces too many false positives, too many unnecessary surgical procedures for benign causes, and has not been shown to reduce ovarian cancer mortality in randomised trials. |
Busting the 7 Most Common Social Media Myths About CA-125
Indian social media — WhatsApp groups, Facebook health forums, and YouTube health channels — is a frequent source of misinformation about CA-125. The consequences range from unnecessary panic to dangerous false reassurance. Below is a direct, evidence-based rebuttal of the 7 most common myths Dr. Mehta encounters in clinical practice.
🚫 MYTH
A high CA-125 means I definitely have cancer.
✅ FACT
An elevated CA-125 does NOT diagnose cancer. The majority of elevated CA-125 results in pre-menopausal women are from completely benign causes — endometriosis, fibroids, PID, pregnancy, liver disease, and even menstruation. CA-125 guides further investigation — it is not a diagnostic test for cancer.
🚫 MYTH
A normal CA-125 means I definitely don't have cancer.
✅ FACT
A normal CA-125 does NOT exclude cancer. Nearly 50% of Stage I ovarian cancers — the most curable stage — have a normal CA-125 at diagnosis. Specific ovarian cancer subtypes (mucinous, clear cell) frequently have normal CA-125 even at advanced stages. Ultrasound is the primary investigation tool for evaluating any ovarian mass.
🚫 MYTH
CA-125 is a screening test — I should get it done every year to check for cancer.
✅ FACT
CA-125 is NOT recommended as an annual cancer screening test for women without symptoms or specific risk factors. Major guidelines (ACOG, SGO, USPSTF, National Cancer Grid of India) do not recommend routine CA-125 screening in average-risk women. Population-level studies (PLCO trial, UKCTOCS) found no reduction in ovarian cancer mortality from routine CA-125 screening.
🚫 MYTH
My CA-125 is 40 — I must have ovarian cancer.
✅ FACT
A CA-125 of 40 in a pre-menopausal woman with endometriosis, during or just after her period, or with any pelvic inflammation is almost certainly NOT from cancer. The number alone means nothing. A result of 40 in a 65-year-old post-menopausal woman with a new ovarian cyst is a completely different clinical situation. Context is everything.
🚫 MYTH
CA-125 can detect all types of gynaecological cancer.
✅ FACT
CA-125 is primarily associated with serous epithelial ovarian cancer. It is unreliable (often normal) in: mucinous ovarian carcinoma, clear cell ovarian carcinoma, early endometrial cancer, most cervical cancers, and borderline ovarian tumours. Different cancers require different tumour markers — a panel approach is needed for comprehensive assessment.
🚫 MYTH
CA-125 can diagnose endometriosis — if it's high, I have it; if it's normal, I don't.
✅ FACT
CA-125 is neither sensitive nor specific enough to diagnose or exclude endometriosis. Stages I and II endometriosis frequently have normal CA-125. An elevated CA-125 does not confirm endometriosis. The gold standard for endometriosis diagnosis remains laparoscopy with biopsy. CA-125 in endometriosis is most useful as a monitoring tool — not a diagnostic one.
🚫 MYTH
A CA-125 result by itself from an online lab report is sufficient to understand my risk.
✅ FACT
A CA-125 number received from an online lab portal without clinical interpretation is a number without meaning. The same CA-125 value of 80 U/mL has completely different implications in a 28-year-old with known endometriosis versus a 62-year-old post-menopausal woman with a new ovarian mass. Every CA-125 result deserves clinical interpretation — not just a report.
All Gynaecological Cancer Tumour Markers in India — Costs & Uses
When investigating a gynaecological mass or suspected cancer, a range of tumour markers may be required — not just CA-125. All costs listed are approximate 2024 reference figures for private laboratory testing in India. At Shree Hospitals, panels are tailored to each patient's specific clinical indication — not ordered as blanket expensive workups.
| Tumour Marker | Approx. Cost (2024) | Primary Clinical Use | Key Facts |
|---|---|---|---|
| CA-125 | ₹500–1,200 | Ovarian cancer, advanced endometrial cancer, cancer monitoring, endometriosis follow-up | Primary tumour marker for epithelial ovarian cancer. Most widely ordered. Elevated in many benign conditions. Available at Shree Hospitals in-house with same-day results. |
| HE4 (Human Epididymis Protein 4) | ₹800–1,500 | Ovarian cancer risk stratification (ROMA score); distinguishing ovarian cancer from endometriosis | More specific than CA-125 — rarely elevated in endometriosis or benign gynaecological conditions. Used together with CA-125 to calculate the ROMA score. Available at Shree Hospitals in-house. |
| CA-125 + HE4 (ROMA Score Package) | ₹1,500–2,800 | Pre-operative risk stratification of ovarian masses; all complex adnexal masses before surgery | The most powerful ovarian malignancy risk assessment tool available. One sample, two markers, one integrated risk score. ROMA score calculation provided alongside marker results at Shree Hospitals. |
| AFP (Alpha-Fetoprotein) | ₹400–800 | Yolk sac tumours, ovarian germ cell tumours (young women / adolescents) | Essential for evaluating ovarian masses in adolescents and young women — germ cell tumours produce very high AFP. Not relevant for epithelial ovarian cancer. |
| Beta-hCG | ₹300–600 | Choriocarcinoma, gestational trophoblastic disease, dysgerminoma | Critical marker for gestational trophoblastic disease (molar pregnancy, choriocarcinoma). Very high sensitivity — levels monitored very carefully during and after treatment. |
| CEA (Carcinoembryonic Antigen) | ₹400–800 | Mucinous ovarian carcinoma; colorectal cancer invading pelvis; appendiceal tumours | Useful when a mucinous ovarian mass is being evaluated — mucinous carcinomas may not elevate CA-125 but often elevate CEA. Also elevated in colorectal and appendiceal cancers that can mimic ovarian cancer. |
| CA 19-9 | ₹500–1,000 | Mucinous ovarian carcinoma; pancreatic cancer; biliary cancer | Another marker for mucinous tumours. Often ordered alongside CA-125 and CEA for complex ovarian masses where mucinous pathology is suspected. |
| Inhibin A / Inhibin B | ₹800–1,500 | Granulosa cell tumours of the ovary; borderline mucinous tumours | Granulosa cell tumours (oestrogen-secreting sex cord-stromal tumours) produce very high inhibin B. Post-menopausal women with elevated inhibin B and ovarian mass should be evaluated for granulosa cell tumour. |
| SCC Antigen (Squamous Cell Carcinoma Antigen) | ₹500–1,000 | Cervical squamous cell carcinoma; monitoring treatment response | The primary tumour marker for squamous cell carcinoma of the cervix. Used for monitoring treatment response and early detection of recurrence. Not useful for adenocarcinoma of the cervix. |
CA-125 and Endometriosis — A Special and Frequently Confused Relationship
The relationship between CA-125 and endometriosis is arguably the area of greatest clinical confusion surrounding this marker in India. Endometriosis affects approximately 10% of women of reproductive age — tens of millions of Indian women — and many of them have elevated CA-125 as a direct result of their endometriosis, not from cancer.
| Endometriosis Stage | Typical CA-125 Level | Disease Characteristics | Clinical Interpretation and Action |
|---|---|---|---|
| Stage I (Minimal) | Typically NORMAL (<35 U/mL) | Superficial peritoneal implants only; no endometriomas; no adhesions | CA-125 is not reliably elevated at Stage I. A normal CA-125 does NOT exclude minimal endometriosis. CA-125 is unhelpful as a diagnostic tool at this stage — laparoscopy is required to confirm or exclude the diagnosis. |
| Stage II (Mild) | Often NORMAL or MILDLY ELEVATED (35–65 U/mL) | More implants; some adhesions; small deposits; no endometriomas | CA-125 may be mildly elevated in some women with Stage II disease, but remains normal in many. Still a poor diagnostic tool at this stage. Clinical history (dysmenorrhoea, dyspareunia) and ultrasound are more informative. |
| Stage III (Moderate) | Often ELEVATED (50–100 U/mL) | Multiple implants; endometriomas (<3cm); significant adhesions | Endometriomas produce more shedding and inflammation — CA-125 is more frequently elevated at this stage. The combination of endometrioma on ultrasound + elevated CA-125 is characteristic. Useful as a baseline before treatment and for monitoring. |
| Stage IV (Severe) | Frequently ELEVATED (often >100 U/mL; occasionally >200 U/mL) | Large endometriomas (>3cm); dense adhesions; tubal occlusion; deep infiltrating endometriosis | At Stage IV, CA-125 can be dramatically elevated — sometimes in ranges traditionally associated with ovarian cancer. The clinical challenge: distinguishing Stage IV endometriosis from malignant transformation requires HE4 (usually normal in endometriosis) + IOTA ultrasound + clinical context (age, menopausal status, rate of CA-125 rise). |
| Post-menopausal Endometriosis | VARIABLE — Any elevation requires careful evaluation | Endometriosis persisting into menopause | Post-menopausal endometriosis with any CA-125 elevation requires evaluation by a Gynecologic Oncologist. The risk of malignant transformation of endometrioma is higher in post-menopausal women — a growing endometrioma after menopause with elevated CA-125 must have IOTA ultrasound + HE4 assessment urgently. |
| After Endometriosis Surgery | Should FALL significantly post-op | Post-laparoscopic excision of endometriosis | A successful endometriosis surgery should reduce CA-125 significantly within 4–8 weeks. Persistent elevation after surgery suggests residual disease. A rise after an initial post-operative fall suggests recurrence. Useful monitoring tool when used as a baseline before and serially after surgery. |
Warning Signs of Possible Malignant Transformation of an Endometrioma
A sudden sharp rise in CA-125 (beyond what previous levels would suggest from endometriosis alone); growth of an endometrioma after menopause; development of solid components within a previously simple endometrioma on ultrasound; or a newly elevated HE4 in a woman whose previous HE4 was normal. Any of these requires urgent Gynecologic Oncology evaluation — even in a woman with long-standing known endometriosis.
CA-125 in Cancer Monitoring — The Marker That Tracks Your Journey
While CA-125's role in cancer diagnosis is limited by its lack of specificity, its role in cancer monitoring — once a cancer diagnosis has been established — is one of the most valuable applications of any tumour marker in all of oncology. A rising or falling CA-125 provides a real-time, quantitative reflection of disease burden that is faster and often more sensitive than imaging.
| Monitoring Phase | Who Needs It | What the CA-125 Tells You and What Happens |
|---|---|---|
| Before First Treatment (Baseline) | All women diagnosed with epithelial ovarian cancer; advanced endometrial cancer (Stage IIIC–IV) | A pre-treatment baseline CA-125 is essential. It establishes the starting point against which all subsequent measurements are compared. A very high baseline (e.g., 1,200 U/mL) with treatment response (falling to 15 U/mL) provides one of the clearest monitoring signals in all of oncology. |
| During Chemotherapy (Every 3-Week Cycle) | Women receiving carboplatin + paclitaxel or other platinum-based chemotherapy for ovarian or endometrial cancer | CA-125 should fall with each cycle of effective chemotherapy. A trajectory of: 800 → 500 → 250 → 90 → 35 → 12 (over 6 cycles) confirms excellent treatment response. A plateau or rise during chemotherapy suggests treatment resistance — the regimen should be reconsidered. |
| After Completing Treatment (Response Assessment) | All treated cancer patients — to confirm complete response (CA-125 within normal range) | After completing primary treatment (surgery + chemotherapy), a CA-125 within the normal range is a key component of confirming complete clinical response. A CA-125 that fails to normalise after completing chemotherapy suggests residual microscopic disease and may inform decisions about maintenance therapy. |
| Surveillance After Remission | All ovarian cancer patients in remission; advanced endometrial cancer patients in remission | CA-125 is the most sensitive single test for early detection of recurrence. It typically begins rising 2–6 months before recurrence becomes detectable on CT imaging or causes clinical symptoms. Regular surveillance (every 3 months for the first 2 years) allows early detection of recurrence when salvage treatment options are most effective. |
| Diagnosis of Recurrence (CA-125 triggering restaging) | Rising CA-125 on surveillance — confirmed on 2 consecutive measurements | When CA-125 begins rising from the post-treatment nadir: if the rise is confirmed on 2 measurements (typically taken 4 weeks apart), CT restaging is arranged. The decision about initiating salvage chemotherapy based on rising CA-125 alone is complex — discussed at MDT and with the patient. |
| PARP Inhibitor Maintenance Monitoring | Women on olaparib, niraparib, or rucaparib maintenance therapy | During PARP inhibitor maintenance, CA-125 is monitored every 3 months alongside FBC and renal function. A rising CA-125 during maintenance therapy may indicate the cancer is becoming resistant to the PARP inhibitor — prompting imaging and consideration of treatment modification. |
What Is the ROMA Score and How Is It Used?
The ROMA score (Risk of Ovarian Malignancy Algorithm) represents the most important advance in ovarian cancer risk stratification in the last two decades. By combining two complementary biomarkers — CA-125 and HE4 — with menopausal status into a single, mathematically validated score, ROMA provides a probability assessment that is significantly more accurate than either marker alone.
Pre-Menopausal Women — LOW RISK
ROMA < 7.4%Probability of epithelial ovarian cancer is low. The ovarian mass is more likely to be a benign cyst (functional, dermoid, endometrioma, benign cystadenoma) than a malignancy. Can be managed conservatively — ultrasound follow-up, possible laparoscopic surgery at a general gynaecology facility.
Pre-Menopausal Women — HIGH RISK
ROMA ≥ 7.4%Meaningful probability of ovarian malignancy. Referral to Gynecologic Oncologist for pre-surgical assessment. Surgery should be performed or directly supervised by a Gynecologic Oncologist to ensure appropriate staging if cancer is confirmed intraoperatively.
Post-Menopausal Women — LOW RISK
ROMA < 25.3%In the post-menopausal context (where all ovarian cysts are by definition abnormal), a ROMA score below 25.3% is relatively reassuring. Conservative management with regular surveillance ultrasound may be appropriate for small, simple-appearing cysts.
Post-Menopausal Women — HIGH RISK
ROMA ≥ 25.3%Significant probability of ovarian malignancy in post-menopausal women. Surgery is strongly recommended and should be performed by a Gynecologic Oncologist with appropriate staging capability — bilateral salpingo-oophorectomy + total hysterectomy + omentectomy + lymph node assessment.
ROMA vs CA-125 Alone — The Clinical Advantage
ROMA correctly classifies approximately 94% of malignant ovarian masses as High Risk, while CA-125 alone correctly classifies only 72–78% of malignant masses. Importantly, ROMA correctly identifies 76% of malignant masses as High Risk even when CA-125 is within the normal range — because HE4 may already be elevated when CA-125 has not yet risen. At Shree Hospitals, ROMA score is calculated from a single blood sample and reported alongside the individual CA-125 and HE4 values.
Why Women Across India Choose Shree Hospitals for CA-125 Interpretation
| Why Shree Hospitals | What This Means for Your CA-125 Journey |
|---|---|
| Dr. Jay Mehta — Dual Expertise: Endometriosis & MCH Gynecologic Oncosurgeon | Dr. Jay Mehta occupies a unique dual position: he is recognised as one of India's foremost endometriosis surgeons AND leads a team with full-time MCH Gynecologic Oncosurgery training. This dual expertise is clinically invaluable — he can correctly identify that a CA-125 of 180 in a 32-year-old with Stage IV endometriosis does not require urgent cancer surgery, while recognising that a CA-125 of 60 in a 55-year-old post-menopausal woman with a complex ovarian mass IS an oncological emergency. No other combination of expertise better serves women with elevated CA-125 results. |
| In-House CA-125 and HE4 Testing — ROMA Score Calculated On-Site | At Shree Hospitals, CA-125 and HE4 are both measured in-house in the on-site pathology laboratory. Results available within 24–48 hours (often same day); no sample transport delay or external laboratory variability; ROMA score automatically calculated from the same blood sample. For women presenting with an ovarian mass who need urgent risk stratification — same-day CA-125 + HE4 + ROMA score + ultrasound is achievable in a single visit. |
| In-House Radiology — IOTA-Protocol Ultrasound | Shree Hospitals has an in-house radiology department with specialist ultrasonography capability. Transvaginal ultrasound using the IOTA (International Ovarian Tumour Analysis) Simple Rules — the internationally validated system for characterising ovarian masses as benign or malignant — is performed as standard for any woman with an ovarian mass, complex cyst, or elevated CA-125. The combination of IOTA-protocol ultrasound + ROMA score at the same visit provides the most comprehensive pre-surgical risk stratification currently available. |
| Complete Care Pathway — From Elevated CA-125 to Diagnosis to Surveillance | Shree Hospitals has a dedicated Department of Gynecologic Oncology — providing the complete care pathway from an elevated CA-125 result through to diagnosis, surgery, chemotherapy, targeted therapy, and long-term surveillance. Women with an abnormal CA-125 are not referred from clinic to clinic — they are assessed, diagnosed, and managed within a single cohesive team. |
| Cost Transparency and Ethics — No Unnecessary Testing | At Shree Hospitals, tumour marker testing is clinically directed. Women are not subjected to a panel of 12 tumour markers 'to be safe' — they are tested for the specific markers their clinical situation indicates. Pricing for all tests is communicated before the tests are ordered. No CA-125 result is handed to a patient as a number on a lab report without interpretation — every result is discussed in clinical context. |
| Online Consultation for CA-125 Result Interpretation Across India | For women outside Mumbai who have received an elevated CA-125 result — Dr. Jay Mehta offers online video consultation for CA-125 result interpretation, review of ultrasound reports, and guidance on whether local management is appropriate or whether referral to Shree Hospitals is advised. Particularly valuable for: women in Tier-2 cities told they have 'high CA-125' without specialist interpretation; women with endometriosis anxious about their CA-125; and women currently on cancer treatment wanting a second opinion on their CA-125 trend. |
Dr. Jay Mehta — The Endometriosis and Gynecologic Oncology Connection
In my clinical practice, I see two kinds of women with elevated CA-125 every week. The first is a 34-year-old with severe endometriosis and a CA-125 of 180 who has been told by three doctors that she 'might have cancer.' She doesn't. She has endometriosis, and her CA-125 is a reflection of her disease burden — not of malignancy. She needs expert endometriosis surgery, not cancer treatment.
The second is a 58-year-old post-menopausal woman with a CA-125 of 48 who was told 'it's only mildly high, nothing to worry about' by a general practitioner. Her ultrasound — which she was not sent for — shows a complex ovarian mass with solid components. She has Stage IIIC ovarian cancer. She needed a Gynecologic Oncologist six months ago.
These two cases illustrate why CA-125 alone, without the right clinical expertise, fails women in both directions — causing unnecessary panic in the first, and dangerous false reassurance in the second. At Shree Hospitals, we interpret CA-125 the right way — every time.
Frequently Asked Questions — CA-125 Test in India
What is the CA-125 test and what does it measure?
CA-125 levels rise when cells are inflamed, disrupted, or multiply abnormally — which happens in both benign conditions (endometriosis, PID) and malignant conditions (ovarian cancer). CA-125 is a simple blood test from a vein. Understanding the distinction between 'tumour-associated' and 'tumour-specific' is the foundation of correct CA-125 interpretation — a CA-125 result without clinical context is like a fever measurement without knowing the patient.
I have a CA-125 of 56. Should I be worried?
The correct action: do NOT catastrophise a CA-125 of 56 without specialist interpretation — but do NOT ignore it either. Book an appointment with Dr. Mehta at Shree Hospitals for a complete assessment: clinical history + pelvic examination + transvaginal ultrasound + HE4 (for ROMA score calculation) interpreted together. A number without context is meaningless — context with a specialist is everything.
What is HE4 and why is it better than CA-125?
However, HE4 has its own limitations — it is elevated in non-gynaecological conditions (particularly kidney disease) and is less sensitive than CA-125 for certain cancer subtypes (clear cell carcinoma). The clinical solution is to use them together: when CA-125 and HE4 are measured from the same blood sample and combined with menopausal status in the ROMA algorithm, the resulting score is significantly more accurate than either marker alone. At Shree Hospitals, HE4 is available in-house and measured simultaneously with CA-125 whenever ROMA score calculation is clinically indicated.
What is the ROMA score and how is it different from CA-125?
ROMA determines whether an ovarian mass should be managed by a general gynaecologist (Low Risk) or must be referred to a Gynecologic Oncologist (High Risk) before surgery. High-ROMA patients who have their surgery performed by an appropriately trained Gynecologic Oncologist have better staging, better cytoreduction, and better survival outcomes than those referred to non-specialist surgeons. At Shree Hospitals, ROMA score is calculated from a single blood sample and reported alongside the individual CA-125 and HE4 values.
I have endometriosis and my CA-125 is 120. Is this cancer?
A CA-125 of 120 in a woman with known endometriosis requires careful interpretation — not panic — by a specialist who can weigh all these factors together. Dr. Jay Mehta is uniquely positioned as both India's leading endometriosis surgeon and a Gynecologic Oncosurgeon to interpret exactly this clinical scenario correctly. Please book a consultation at Shree Hospitals for a comprehensive assessment including ROMA score calculation.
When is CA-125 really mandatory versus optional?
The false positive rate from routine screening is too high — elevated CA-125 from benign causes leads to unnecessary investigations, anxiety, and sometimes unnecessary surgery. If you are unsure whether you need a CA-125 test, the best person to ask is a Gynecologic Oncologist like Dr. Jay Mehta — who can make that judgment based on your specific clinical situation, not a lab, not the internet, and not a friend.
How often should I get a CA-125 test if I have ovarian cancer?
At Shree Hospitals, all ovarian cancer patients are enrolled in a structured surveillance programme with scheduled CA-125 measurements, and a direct-access pathway to contact Dr. Mehta's team immediately if CA-125 rises between appointments. Early detection of recurrence means more treatment options and better outcomes — do not wait for your next scheduled appointment if your CA-125 is rising.
I am 55 and post-menopausal. My CA-125 is 42. What does this mean?
If the ultrasound is completely normal and HE4 is normal (ROMA score Low Risk): the CA-125 of 42 in a post-menopausal woman is still not entirely explained, but the cancer risk is low. Further investigation may involve liver function tests (to exclude liver disease) and a repeat CA-125 in 6 weeks. If the ultrasound shows any ovarian cyst or complex mass: this is an urgent situation requiring ROMA-guided surgical planning by a Gynecologic Oncologist. Please call Dr. Mehta's team at +91-9920914115 immediately.
My CA-125 was high after my first chemotherapy cycle. Does this mean the treatment isn't working?
However, a CA-125 that is consistently rising (not a transient spike) across multiple cycles IS a concerning signal of treatment resistance and should be discussed with the oncology team. The pattern that matters is the TREND over multiple measurements — not any single data point. At Shree Hospitals, your CA-125 trajectory is reviewed at every chemotherapy visit and assessed by the Multidisciplinary Team if the trend is worrying.
My CA-125 is rising on surveillance — what happens now?
Do NOT wait for your next scheduled appointment if your CA-125 is rising. Contact Shree Hospitals immediately at +91-9920914115 and the team will arrange urgent assessment. Early detection of recurrence means more treatment options and better outcomes. Salvage treatments available: second-line chemotherapy, PARP inhibitor, surgery for resectable recurrence, radiotherapy for focal recurrence, immunotherapy for MSI-high disease.
Why do women across India choose Shree Hospitals for CA-125 interpretation?
Women from across India — Maharashtra, Gujarat, Rajasthan, Madhya Pradesh, Chhattisgarh, and beyond — choose Shree Hospitals specifically because the combination of Dr. Mehta's endometriosis and oncology expertise is not available elsewhere. The same CA-125 value of 80 U/mL needs completely different management in a 28-year-old with known endometriosis versus a 62-year-old post-menopausal woman with a new ovarian mass — and only a specialist who understands both clinical contexts can interpret it correctly.
🚨 CA-125 Result — When to Seek Specialist Evaluation
Never interpret a CA-125 result in isolation. These situations demand specialist review:
- Your CA-125 result is above 35 U/mL and you have NO known benign cause (not pregnant, not on your period, no known endometriosis) — seek specialist evaluation
- Your CA-125 was previously normal and has now risen significantly — even if still below 35, a doubling or rapid rise warrants investigation
- CA-125 is elevated AND your ultrasound shows an ovarian mass, complex cyst, or ascites — urgent Gynecologic Oncology review needed
- You are post-menopausal with ANY elevation in CA-125 — the threshold for concern is lower after menopause; all elevations need evaluation
- You have known endometriosis and your CA-125 has suddenly risen significantly — ask for an IOTA ultrasound and ROMA score assessment
- You are on cancer treatment and your CA-125 — which was falling — has started to rise again — possible treatment failure or recurrence; contact your oncologist immediately
- You had ovarian or endometrial cancer surgery and your CA-125 is rising on follow-up — report this to Dr. Mehta's team immediately, do not wait for your next scheduled appointment
- Your doctor has ordered a CA-125 but has not explained what the result means — you deserve a proper interpretation from a specialist, not a number without context
Consult Dr. Jay Mehta — Get the Right CA-125 Interpretation
A CA-125 result is not an answer — it is a question. The answer requires a clinician who understands the full context: your age, your symptoms, your menopausal status, your history of endometriosis or other pelvic conditions, your ultrasound findings, and your HE4 value for the ROMA score. Dr. Jay Mehta at Shree Hospitals provides exactly this — comprehensive, expert CA-125 interpretation integrated into a complete gynaecological assessment. Online consultation available for women across India.
✅ In-house CA-125 & HE4 ✅ ROMA Score ✅ In-house Radiology ✅ King of Endometriosis ✅ MCH Gynec Oncosurgeon
© Department of Gynecologic Oncology, Shree Hospitals, Mumbai, India. All rights reserved. Content may not be reproduced without written permission. | Primary keyword: CA-125 test India | Secondary: CA-125 blood test interpretation, ROMA score India, HE4 test India, ovarian cancer tumour markers India | LSI Location: CA-125 endometriosis, gynaecological oncology Mumbai India
